Earkart Limited has expanded its global footprint by incorporating a foreign subsidiary, Earkart Health Limited, in the United Kingdom. The new entity was established on June 8, 2026, with a Certificate of Incorporation issued by the relevant UK authorities. This strategic move allows the parent company to enter the healthcare sector, which aligns with its main line of business, ensuring operational synergy and market expansion.

The subsidiary has been incorporated to provide healthcare services and sell healthcare products and other related items. Earkart Health Limited is classified as a related party transaction under the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the Promoters, Promoter Group, and other Group Companies hold no interest in the transaction other than the stated shareholding.

Earkart Limited subscribed to 650 equity shares of GBP 10 each, constituting 65% of the paid-up share capital of Earkart Health Limited. The subscription was made entirely in cash, amounting to a total investment of GBP 6,500. The shares were acquired at face value, and the subsidiary currently holds an authorised and paid-up share capital of GBP 10,000.

Financial and Operational Details

The incorporation did not require any specific governmental or regulatory approvals beyond standard registration formalities in the United Kingdom. As a newly incorporated entity, Earkart Health Limited currently reports nil turnover and has no active business operations. The company is poised to commence activities in the healthcare industry, focusing on services and allied products.

The disclosure was submitted to BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Preeti Srivastava, Company Secretary & Compliance Officer of Earkart Limited, confirmed the development on June 22, 2026. The information is now available on the company's official website.

The Board of Directors of Earkart Limited , at their meeting held on 29 May 2026, approved the incorporation of two wholly-owned subsidiaries (WOS)—Earkart Pharmaceuticals Private Limited and Earkart Healthcare Services Private Limited. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the said regulations. The intimation was filed from Noida and signed by Preeti Srivastava, Company Secretary & Compliance Officer (Membership No: A31615).

Key Details of the Proposed Subsidiaries

Both proposed entities are yet to be incorporated and will, upon incorporation, become wholly-owned subsidiaries and related parties of Earkart Limited and its other subsidiaries. The promoters, promoter group, and group companies have no interest in the proposed entities beyond what is stated above. The following table summarises the key parameters for each proposed WOS:

Business Objectives of the Proposed Entities

The two subsidiaries have been proposed with distinct operational mandates within the broader healthcare space:

• Earkart Pharmaceuticals Private Limited is being incorporated to manufacture, promote, sell, and distribute pharmaceuticals and other related products.
• Earkart Healthcare Services Private Limited is being incorporated to provide services in the healthcare sector.

Regulatory Compliance and Disclosure

The intimation was made in compliance with Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and in accordance with circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026. No governmental or regulatory approvals are required for the incorporation of either proposed subsidiary. The company has stated that further details will be made available on its website at https://www.earkart.in .